Journal of Personalized Medicine最新文献

{"title":"High Cerebral Oxygen Saturation Levels During One-Lung Ventilation Predict Better Cognitive and Clinical Outcomes After Thoracic Surgery: A Retrospective Observational Study.","authors":"Ignacio Garutti, Francisco de la Gala, Javier Hortal, Almudena Reyes, Elena de la Fuente, David Martinez-Gascueña, Carlos Alberto Calvo, Santiago Hernández, Estrela Caamaño, Carlos Simón, Elena Vara, Patricia Piñeiro","doi":"10.3390/jpm15090445","DOIUrl":"10.3390/jpm15090445","url":null,"abstract":"<p><p><b>Background:</b> Cerebral desaturation during one-lung ventilation (OLV) in thoracic surgery has been associated with postoperative cognitive dysfunction (POCD). While the adverse effects of low intraoperative regional cerebral oxygen saturation (rScO₂) are well documented, the potential clinical value of maintaining supranormal rScO₂ levels has not been thoroughly studied. <b>Methods:</b> We conducted a retrospective observational study based on a previously collected cohort from a tertiary university hospital. Adult patients undergoing elective thoracic surgery between January 2019 and December 2022 were included, provided they received lidocaine either intravenously or via a paravertebral block as part of a standardized anesthetic protocol. Patients were divided into the following two groups based on their mean INVOS values 30 min into OLV: those with rScO₂ ≥75% (H-INVOS group) and <75% (L-INVOS group). Intraoperative physiological variables, inflammatory biomarkers, cognitive function via the Mini-Mental State Examination, and postoperative outcomes were analyzed. <b>Results:</b> The H-INVOS group exhibited significantly higher preoperative lung function, higher PaO₂ and PaCO₂ values during OLV, and higher hemoglobin concentrations across all timepoints. They also demonstrated better preservation of cognitive function, lower IL-18 expression at 24 h postoperatively, and shorter hospital stays. There were no statistically significant differences in intraoperative hemodynamics or ventilatory mechanics.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diabetes Phenotypes in Patients Presenting a Myocardial Infarction: Progress Towards Precision Medicine?","authors":"Christelle Lacqua, Arnaud Barbou, Marianne Zeller, Ludwig Serge Aho Glele, Héloïse Adam, Florence Bichat, Jean-Michel Petit, Yves Cottin, Mathieu Boulin","doi":"10.3390/jpm15090444","DOIUrl":"10.3390/jpm15090444","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Despite advances in personalized medicine, diabetes classification and management have remained widely unchanged for decades. The aims of the present study were to determine profiles of patients with type 2 diabetes at the time of their myocardial infarction and to assess 1-year cardiovascular events. <b>Methods</b>: All type 2 diabetic patients admitted for myocardial infarction in our Coronary Intensive Care Unit between 1 April 2021 and 30 June 2023 were included in this retrospective study. To identify patient profiles, we performed a data-driven cluster analysis based on the <i>k</i>-means method according to six characteristics considered as the most relevant in the literature (age at diabetes diagnosis, body mass index, glycated hemoglobin, glutamate decarboxylase antibodies, insulin resistance and beta-cell function). Cox multivariate models were used to identify predictors of 1-year cardiovascular event- and major adverse cardiovascular event-free survivals. <b>Results:</b> This study included 250 patients with a median age of 71 years. Our cluster repartition was as follows: 46% patients presented a severe insulin-deficient diabetes, 3% a severe insulin-resistant diabetes, 16% a mild obesity-related diabetes, 33% a mild age-related diabetes, and 2% patients suffered from a severe autoimmune diabetes. In multivariate analyses, the only independent factor for both longer cardiovascular event- and major adverse cardiovascular event-free survival was a higher glomerular function rate (hazard ratio of 0.97 and 0.98 per 1 mL/mn/1.73 m²; <i>p</i> = 0.01 and <i>p</i> = 0.03, respectively). <b>Conclusions</b>: This study suggests that the severe insulin-deficient diabetes and mild age-related diabetes pathophysiological phenotypes, easily estimated using insulin resistance and beta-cell function as well as age at diabetes diagnosis, body mass index, and glycated hemoglobin, were more frequent among diabetic patients at the time of their myocardial infarction. In daily clinical practice, caution is needed for patients with a low glomerular function rate, as this was associated with shorter cardiovascular event- and major adverse cardiovascular event-free survival at 1-year.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Future of Valvular Heart Disease and Structural Heart Interventions: Why So Much Excitement?","authors":"Eirini Beneki, Julia Grapsa","doi":"10.3390/jpm15090443","DOIUrl":"10.3390/jpm15090443","url":null,"abstract":"<p><p>Valvular heart disease (VHD) is becoming increasingly prevalent in the aging population and continues to be a major contributor to cardiovascular morbidity and mortality. Advances in non-invasive imaging, able to confirm the presence and severity of valve disease, have been crucial in revealing VHD mechanisms through the assessment of morphological and functional changes. In parallel, immense progress in both surgical techniques and catheter-based interventions has broadened therapeutic options, particularly for high-risk and elderly patients. Despite the availability of evidence-based guidelines, a shared decision-making process should play a key role in the final decision for therapy, outlining the goals and risks of possible intervention coupled with the patient's own needs and expectations. Future research should aim to develop safer, more effective, and longer-lasting treatments tailored to the unique need of each patient with VHD.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Age at Onset on the Clinical Course and Biochemical Parameters of Anorexia Nervosa.","authors":"Lorenzo Ferrario, Andrea Costantino, Letizia Maria Affaticati, Massimo Clerici, Antonios Dakanalis, Enrico Capuzzi, Massimiliano Buoli","doi":"10.3390/jpm15090442","DOIUrl":"10.3390/jpm15090442","url":null,"abstract":"<p><p><b>Background:</b> Anorexia nervosa (AN) has the highest mortality rate among psychiatric disorders, making early diagnosis and tailored management crucial. This study aimed to evaluate the impact of age at onset (AAO)-childhood/adolescence versus adulthood-on the clinical course and associated biochemical parameters. <b>Methods:</b> Seventy-six female patients with AN were divided into two groups based on AAO (<18 years vs. ≥18 years). Group comparisons were performed using <i>t</i>-tests for continuous variables and χ² tests for categorical variables. Correlation analyses assessed associations between AAO and continuous variables. Significant findings were entered into regression models, including a binary logistic regression with AAO as the dependent variable and a linear regression with significant correlations as predictors. <b>Results:</b> The early-onset group showed significantly higher potassium levels and a lower sodium/potassium ratio (Na⁺/K⁺) compared with the late-onset group (potassium: t = 0.93, <i>p</i> < 0.01; Na⁺/K⁺: t = 3.39, <i>p</i> < 0.01). AAO was strongly inversely correlated with potassium levels (r = -0.75, <i>p</i> < 0.01) and positively correlated with cholesterol (r = 0.574, <i>p</i> < 0.01) and Na⁺/K⁺ (r = 0.78, <i>p</i> = 0.01). Binary logistic regression correctly classified 87% of cases, showing that lower Na⁺/K⁺ was associated with earlier onset (OR = 2.23, <i>p</i> = 0.03). Linear regression confirmed significant associations of AAO with cholesterol levels (B = 0.07, <i>p</i> = 0.02) and Na⁺/K⁺ (B = 1.68, <i>p</i> < 0.01). <b>Conclusions:</b> AAO in AN is strongly associated with specific biochemical parameters. Early-onset patients exhibit more severe electrolyte imbalances, while late-onset cases show higher cholesterol levels, suggesting increased cardiovascular risk. These findings emphasize the importance of personalized treatment approaches according to AAO, although further studies are warranted to confirm these results.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Precision Paradigm in Periodontology: A Multilevel Framework for Tailored Diagnosis, Treatment, and Prevention.","authors":"Gianna Dipalma, Angelo Michele Inchingolo, Francesco Inchingolo, Irene Palumbo, Lilla Riccaldo, Mariafrancesca Guglielmo, Roberta Morolla, Andrea Palermo, Grazia Marinelli, Alessio Danilo Inchingolo","doi":"10.3390/jpm15090440","DOIUrl":"10.3390/jpm15090440","url":null,"abstract":"<p><p><b>Background</b>: Precision medicine in periodontology seeks to individualize prevention, diagnosis, and treatment based on biological, genetic, behavioral, and environmental factors. This approach addresses the limitations of standardized protocols, which often fail to consider patient-specific variability in disease susceptibility and progression. <b>Materials and Methods</b>: A systematic review was conducted following PRISMA guidelines and registered in PROSPERO (ID: CRD42024593760). Searches were performed in PubMed, Scopus, and Web of Science (2014-2025) using terms related to precision and personalized medicine in periodontology. Studies were screened based on predefined inclusion criteria, and risk of bias was assessed using the ROBINS tool. <b>Results</b>: Sixteen studies met the inclusion criteria. Diagnostic tools integrating biomarkers (e.g., IL-1β, salivary and GCF proteomics) and digital platforms (e.g., flowcharts and decision support systems) showed improved accuracy and early disease detection. Personalized treatments, including host-modulating therapies and customized antibiotics, improved clinical outcomes. Tailored preventive strategies based on genetic, systemic, and behavioral risk profiling reduced tooth loss and optimized care frequency. <b>Conclusions</b>: Precision periodontology enhances patient-centered care by integrating omics technologies, real-time diagnostics, and behavioral insights. This paradigm improves diagnostic precision, therapeutic outcomes, and long-term prevention, supporting its broader implementation in clinical practice.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cluster-Based Immunization Patterns in Diabetes Mellitus: Insights for Personalized Preventive Care.","authors":"Teresa Gisinger, Alexandra Kautzky-Willer, Michael Leutner","doi":"10.3390/jpm15090441","DOIUrl":"10.3390/jpm15090441","url":null,"abstract":"<p><p><b>Background</b>: We investigated immunization status and preventive care among diabetes mellitus (DM) patients by stratifying them into clinically distinct risk clusters based on comorbidities, reflecting a personalized medicine approach. <b>Methods</b>: Using the Austrian health interview survey 2019, we identified four groups: cluster 1 (DM, arterial hypertension (aHTN), dyslipidemia; <i>n</i> = 215), cluster 2 (DM, aHTN, dyslipidemia, obesity class II; <i>n</i> = 33), cluster 3 (DM, aHTN, dyslipidemia, depression; <i>n</i> = 65), and a control cohort (DM without hyperlipidemia, hypertension, depression, or obesity class II; <i>n</i> = 214). The cohorts were compared by chi² tests. By logistic regression the association of the cluster-related variables and the vaccination status/preventive care variables were analyzed. <b>Results:</b> Significant differences in intact diphtheria immunization between the cohorts exist (cluster 1: 45.6%, cluster 2: 27.3%, cluster 3: 52.3%, control: 51.9%, <i>p</i>-value 0.047). Differences in intact tetanus (42.4% vs. 64%, <i>p</i> = 0.027) and diphtheria (27.3% vs. 51.9%, <i>p</i> = 0.013) immunization between cluster 2 and control cohort were investigated. Cluster 2 was negatively associated with tetanus (OR 0.83, <i>p</i> = 0.009) and diphtheria (OR 0.85, <i>p</i> = 0.018) immunization. Cluster 1 reports higher rates of fecal occult blood test (50.7% vs. 39.3%, <i>p</i> = 0.022) and cluster 2 reports a higher rate of colonoscopy (24.2% vs. 8.9%, <i>p</i> = 0.015) in comparison to the control cohort. <b>Conclusions</b>: A personalized medicine approach reveals that DM patients with specific comorbidity patterns, particularly those with hypertension, dyslipidemia, and obesity class II, have lower immunization rates-highlighting the need for targeted preventive strategies.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Insulin Resistance with Dysglycemia in Elder Koreans: Age- and Sex-Specific Cutoff Values.","authors":"Sang Min Yoon, Boyoung Park","doi":"10.3390/jpm15090438","DOIUrl":"10.3390/jpm15090438","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Dysglycemia including pre-diabetes mellitus (Pre-DM) and type 2 diabetes mellitus (T2DM) is associated with insulin resistance. This study aimed to support personalized early diagnosis of dysglycemia by proposing optimal, sex- and age-specific cutoff values for Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Homeostatic Model Assessment of Beta-Cell Function (HOMA-β) in Koreans aged ≥65 years. <b>Methods</b>: This study analyzed 3862 older Koreans from the 8th Korea National Health and Nutrition Examination Survey data (2019-2021), excluding those with prior diabetes or medication. The participants were classified into normal and dysglycemia groups, based on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c). Sex- and age-specific optimal cutoff values were determined using Youden's Index (YI) and area under the curve (AUC). <b>Results</b>: For T2DM, the optimal HOMA-IR cutoff was 2.25 for men and 2.03 for women, with strong discriminative performance (AUCs: 0.828 and 0.823, respectively). Stratifying cutoff values further by sex and age improved the diagnostic accuracy (AUC > 0.83 in most subgroups), underscoring the value of tailored thresholds. For pre-DM, the HOMA-IR cutoff was 1.73 in men and 1.85 in women (AUCs: 0.682 and 0.665, respectively). Age- and sex-specific cutoffs modestly improved AUCs, particularly in men (up to 0.7), although the improvement was less consistent among women. HOMA-β showed no significant association with dysglycemia, and no meaningful cutoff values were identified. <b>Conclusions</b>: HOMA-IR is a promising marker for the early identification of dysglycemia in older adults when interpreted through a personalized lens. Applying sex- and age-specific cutoff values enhances diagnostic precision and supports a more individualized approach to metabolic risk assessment. Further longitudinal studies are warranted to validate these personalized thresholds and to optimize early detection strategies in diverse populations.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection.","authors":"Amer E Alkhalifa, Abdulrahman Al Mokhlf, Hande Ali, Nour F Al-Ghraiybah, Vasiliki Syropoulou","doi":"10.3390/jpm15090437","DOIUrl":"10.3390/jpm15090437","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most common cause of dementia, pathologically defined by extracellular amyloid-β (Aβ) plaques and intracellular tau neurofibrillary tangles. Recent U.S. Food and Drug Administration (FDA) approvals of anti-amyloid monoclonal antibodies (mAbs) aducanumab, lecanemab, and donanemab represent the first disease-modifying therapies for early AD. These therapies have generated both optimism and controversy due to modest efficacy and safety concerns, particularly amyloid-related imaging abnormalities (ARIAs). This review synthesizes current evidence on the efficacy, safety, and biomarker-guided use of anti-Aβ mAbs in AD. <b>Methods:</b> We searched PubMed, Scopus, Web of Science, and Google Scholar to 31 July 2025 for studies on anti-amyloid mAbs in AD. Sources included peer-reviewed articles and regulatory reports. The extracted data covered study design, population, amyloid confirmation, dosing, outcomes, biomarkers, ARIA incidence, and management. <b>Results:</b> Anti-amyloid mAbs consistently demonstrated robust amyloid clearance and modest slowing of clinical decline in early symptomatic AD. Differences emerged across agents in efficacy signals, safety profiles, and regulatory outcomes. Lecanemab and donanemab showed more consistent cognitive benefits, while aducanumab yielded mixed findings, leading to its withdrawal. ARIAs were the most frequent adverse events, occurring more often in APOE ε4 carriers and typically during early treatment. Biomarker analyses also revealed favorable downstream effects, including reductions in phosphorylated tau and markers of astroglial injury, supporting engagement of disease biology. <b>Conclusions:</b> Anti-amyloid mAbs provide proof of concept for AD modification, with the greatest benefit in early disease stages and moderate tau burden. Optimal use requires biomarker confirmation of the amyloid, careful tau staging, and genetic risk assessment. While limitations remain, these therapies represent a pivotal step toward precision neurology and may serve as a foundation for multimodal strategies targeting tau, neuroinflammation, and vascular pathology.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalizing Cochlear Implant Care in Single-Sided Deafness: A Distinct Paradigm from Bilateral Hearing Loss.","authors":"Emmeline Y Lin, Stephanie M Younan, Karen C Barrett, Nicole T Jiam","doi":"10.3390/jpm15090439","DOIUrl":"10.3390/jpm15090439","url":null,"abstract":"<p><p><b>Background:</b> Cochlear implants (CIs) serve diverse populations with hearing loss, but patients with single-sided deafness (SSD) often show lower post-implantation usage and satisfaction than bilateral CI users. This disparity may stem from their normal contralateral ear providing sufficient auditory input for many daily situations, reducing the perceived need for consistent CI use. Consequently, uniform screening and evaluations, typically designed for bilateral hearing loss, often fail to address SSD's unique needs. <b>Methods:</b> This narrative review synthesizes the current literature to explore patient and device factors shaping CI integration, outcomes, and experience in SSD. It highlights implications for developing personalized care strategies distinct from those used in bilateral hearing loss. <b>Results:</b> SSD patients face unique challenges: reliance on compensatory behaviors and significant auditory processing difficulties like acoustic-electric mismatch and place-pitch discrepancy. Anatomical factors and deafness of duration also impact outcomes. Traditional measures are often insufficient due to ceiling effects. Music perception offers a sensitive metric and rehabilitation tool, while big data and machine learning show promise for predicting outcomes and tailoring interventions. <b>Conclusions:</b> Optimizing CI care for SSD necessitates a personalized approach across candidacy, counseling, and rehabilitation. Tailored strategies, including individualized frequency mapping, adaptive auditory training, advanced outcome metrics like music perception, and leveraging big data for precise, data-driven predictions, are crucial for improving consistent CI usage and overall patient satisfaction.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12471390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Journal of Personalized Medicine</i>-Aims and Scope Update.","authors":"Kenneth P H Pritzker","doi":"10.3390/jpm15090436","DOIUrl":"10.3390/jpm15090436","url":null,"abstract":"<p><p><i>Journal of Personalized Medicine</i> (<i>JPM</i>) [...].</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 9","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12470979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}